| Name | Title | Contact Details |
|---|
UltraRAD Corp is a West Berlin, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Med Vsision TeleHealth is a Annapolis, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Cenduit is the leading IRT systems specialist in the world, with rapid study startup software, clinical supply chain intelligence, clinical operations know-how and customer-centric CORE teams making sure your study starts quickly and runs smoothly. Other IRT-driven services include patient randomization and trial supply management (RTSM), integration, patient engagement and materials forecasting. We have over 500 experts worldwide in the US, UK, Switzerland, India, Japan and China, with clinical trial experience in more than 100 countries, interacting with more than 600,000 patients at more than 32,000 sites. Let Cenduit`s experts ensure that your study needs are met on time and within budget.
"Eleven uses its proprietary technology platform to create first-of-a-kind protein therapeutics to address unmet needs for ophthalmic diseases. Proteins are able to modulate inflammatory cytokines, key targets in ocular disease that have been difficult to access with conventional therapeutic approaches. A significant untapped opportunity exists for protein therapeutics to address ophthalmic diseases, and Eleven is applying its advanced protein technology and expertise to develop innovative medicines for patients suffering from ocular diseases. Eleven`s team of industry veterans has deep experience in understanding protein science and biologic drug development, designing and conducting clinical trials and, most importantly, applying specific expertise in ophthalmic disease to create novel ocular therapeutics to treat unmet medical needs. Eleven has developed a proprietary pipeline of ophthalmic drug candidates derived from the company`s innovative AMP-Rx protein engineering technology. The company`s initial product candidates are focused on targeting inflammatory cytokines and key targets of ocular disease by blocking the cytokines and modulating the biological processes that drive ocular disease. Current pipeline opportunities include ocular surface diseases such as dry eye disease (DED) and allergic conjunctivitis (AC), and back of the eye diseases such as diabetic macular edema (DME) and uveitis. In addition, Eleven’s proprietary technology has been utilized to prolong the intravitreal half-life of our pipeline products. Beyond its internal drug development programs, Eleven works with collaborators, such as ThromboGenics, to apply its innovative protein therapeutic design capabilities to engineer and develop biotherapeutic products for additional therapeutic targets. EBI-005, Eleven`s lead product candidate, is a novel interleukin-1 (IL-1) receptor antagonist in Phase 3 clinical development as one of the first topically administered proteins for the treatment of DED and AC, two inflammatory diseases at the surface of the eye."